. "Intern\u00ED medic\u00EDna pro praxi" . . "2" . . "Metformin a jeho postaven\u00ED v l\u00E9\u010Db\u011B diabetes mellitus 2. typu"@cs . "Metformin and its position in the treatment of type 2 diabetes mellitus"@en . "V\u00FDskyt diabetes mellitus zejm\u00E9na 2. typu v sou\u010Dasn\u00E9 dob\u011B stoup\u00E1 prakticky ve v\u0161ech vysp\u011Bl\u00FDch zem\u00EDch sv\u011Bta. Ned\u00E1vno ukon\u010Den\u00E9 velk\u00E9 studie ukazuj\u00ED, \u017Ee nejz\u00E1sadn\u011Bj\u0161\u00EDm faktorem ovliv\u0148uj\u00EDc\u00EDm dlouhodob\u00FD v\u00FDskyt komplikac\u00ED u diabetik\u016F je v\u010Dasn\u00E1 diagnostika diabetu a jeho intenzivn\u00ED l\u00E9\u010Dba bezprost\u0159edn\u011B po diagn\u00F3ze. Metformin, prepar\u00E1t ze skupiny biguanind\u016F, je l\u00E9kem prvn\u00ED volby u v\u0161ech diabetik\u016F 2. typu, u kter\u00FDch nejsou p\u0159\u00EDtomny kontraindikace jeho pod\u00E1v\u00E1n\u00ED. Tento l\u00E9k by m\u011Bl b\u00FDt nasazen bezprost\u0159edn\u011B po diagn\u00F3ze diabetu a jeho d\u00E1vka postupn\u011B titrov\u00E1na na 2-3 g/denn\u011B. V\u016Fd\u010D\u00ED postaven\u00ED metforminu v algoritmu l\u00E9\u010Dby diabetu 2. typu je d\u00E1no jeho dobrou \u00FA\u010Dinnost\u00ED a bezpe\u010Dnost\u00ED, n\u00EDzkou cenou, prok\u00E1zan\u00FDm ochrann\u00FDm efektem proti makro- i mikrovaskul\u00E1rn\u00EDmkomplikac\u00EDm diabetu a jeho p\u0159edpokl\u00E1dan\u00FDmi dal\u0161\u00EDmi pozitivn\u00EDmi \u00FA\u010Dinky v\u010Detn\u011B ochrann\u00E9ho vlivu proti vzniku n\u011Bkter\u00FDch malignit. C\u00EDlem toho \u010Dl\u00E1nku je shrnout sou\u010Dasn\u00E9 poznatky a praktick\u00E9 aspekty vyu\u017Eit\u00ED metforminu v l\u00E9\u010Db\u011B diabetes mellitus 2. typu." . . . "http://www.internimedicina.cz/pdfs/int/2014/02/05.pdf" . "RIV/00216208:11110/14:10282694" . . "Haluz\u00EDk, Martin" . . "1"^^ . "[D0374A02FF78]" . "28600" . . "16" . . "The prevalence of type diabetes mellitus, in particular type 2, is currently increasing worldwide. Recent large scale studies have shown that the most important factor influencing the rate of long term complications in patients with diabetes is its timely diagnosis and early intensive treatment starting immediately after diagnosis combined with efficacious intervention of other cardiovascular risk factors. Metformin, the drug from the biguanide group, represents the first choice treatment in all patients with type 2 diabetes who do not have contraindications of its use. Metformin treatment should be started right after the diagnosis of diabetes and titrated up to 2-3 grams/day. The leading position of metformin in type 2 diabetes treatment algorithm is due to its good efficacy and safety, low cost, established protective effects against macro- and microvascular complications of diabetes and its other positive effects including an-ticipated protection against some malignancies. The aim of this paper is to summarize current knowledge and practical aspects of the use of metformin in the treatment of type 2 diabetes."@en . . "cardiovascular complications; hypoglycemia; metformin; oral antidiabetic drugs; Type 2 diabetes mellitus"@en . . . "RIV/00216208:11110/14:10282694!RIV15-MSM-11110___" . "1"^^ . . "V\u00FDskyt diabetes mellitus zejm\u00E9na 2. typu v sou\u010Dasn\u00E9 dob\u011B stoup\u00E1 prakticky ve v\u0161ech vysp\u011Bl\u00FDch zem\u00EDch sv\u011Bta. Ned\u00E1vno ukon\u010Den\u00E9 velk\u00E9 studie ukazuj\u00ED, \u017Ee nejz\u00E1sadn\u011Bj\u0161\u00EDm faktorem ovliv\u0148uj\u00EDc\u00EDm dlouhodob\u00FD v\u00FDskyt komplikac\u00ED u diabetik\u016F je v\u010Dasn\u00E1 diagnostika diabetu a jeho intenzivn\u00ED l\u00E9\u010Dba bezprost\u0159edn\u011B po diagn\u00F3ze. Metformin, prepar\u00E1t ze skupiny biguanind\u016F, je l\u00E9kem prvn\u00ED volby u v\u0161ech diabetik\u016F 2. typu, u kter\u00FDch nejsou p\u0159\u00EDtomny kontraindikace jeho pod\u00E1v\u00E1n\u00ED. Tento l\u00E9k by m\u011Bl b\u00FDt nasazen bezprost\u0159edn\u011B po diagn\u00F3ze diabetu a jeho d\u00E1vka postupn\u011B titrov\u00E1na na 2-3 g/denn\u011B. V\u016Fd\u010D\u00ED postaven\u00ED metforminu v algoritmu l\u00E9\u010Dby diabetu 2. typu je d\u00E1no jeho dobrou \u00FA\u010Dinnost\u00ED a bezpe\u010Dnost\u00ED, n\u00EDzkou cenou, prok\u00E1zan\u00FDm ochrann\u00FDm efektem proti makro- i mikrovaskul\u00E1rn\u00EDmkomplikac\u00EDm diabetu a jeho p\u0159edpokl\u00E1dan\u00FDmi dal\u0161\u00EDmi pozitivn\u00EDmi \u00FA\u010Dinky v\u010Detn\u011B ochrann\u00E9ho vlivu proti vzniku n\u011Bkter\u00FDch malignit. C\u00EDlem toho \u010Dl\u00E1nku je shrnout sou\u010Dasn\u00E9 poznatky a praktick\u00E9 aspekty vyu\u017Eit\u00ED metforminu v l\u00E9\u010Db\u011B diabetes mellitus 2. typu."@cs . "Metformin a jeho postaven\u00ED v l\u00E9\u010Db\u011B diabetes mellitus 2. typu" . "CZ - \u010Cesk\u00E1 republika" . . "V" . . "Metformin and its position in the treatment of type 2 diabetes mellitus"@en . "1212-7299" . "11110" . "Metformin a jeho postaven\u00ED v l\u00E9\u010Db\u011B diabetes mellitus 2. typu"@cs . "Metformin a jeho postaven\u00ED v l\u00E9\u010Db\u011B diabetes mellitus 2. typu" . . "3"^^ .